Kornimate/medical-research-clean huggingface dataset:
biweekly tpf induction chemotherapy for locally advanced squamous cell carcinoma of head and neck

Conditions: Locally Advanced Head and Neck Carcinoma

Summary: this study aimed to assess the efficacy and safety for biweekly tpf as induction chemotherapy for locally advanced head and neck cancer

after being informed the study and potential risk, patients was provided written informed consent prior to initiating therapy. the chemotherapy regimen including docetaxel, cisplatin, 5-fluorouracil, and leucovorin was administered every 14 days for six cycles or until disease progression or intolerant treatment toxicity.

Eligibility criteria:
inclusion criteria: 1. the patient has histopathologically or cytologically confirmed diagnosis of stage 3 or 4 squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx. 2. the patient has local advanced, and no distant metastatic, and unresectable disease. 3. the patient has measurable or valuable disease. 4 age ≥ 20 years. 5. ecog performance status 0, 1 or 2 at study entry. 6. life expectancy ≥ 3 months. 7. the patient must have adequate organ function, defined as: 7a absolute neutrophil count (anc) ≥ 1.5 x 109/l; platelets ≥ 100 x 109/l; hemoglobin * 9.0 g/dl. 7b total bilirubin ≤ 1.5 times upper limit of normal (uln); aspartate transaminase (ast) and alanine transaminase (alt) ≤ 2.5 x uln. 7c alkaline phosphatase ≤ 2.5 x uln. 7d serum creatinine ≤ 1 x uln or creatinine clearance ≥ 60 ml/min/1.73 m2. 8. signed informed consent. 9 women of child-bearing potential and men must be willing and able practice adequate contraception prior to study entry and for the duration of study treatment. exclusion criteria: 1. the patient had previous chemotherapy or radiotherapy for squamous cell carcinoma of head and neck. 2. the patient has uncontrolled disorder(s), serious illness or medical condition(s) is/are not be enrolled to study that be confirmed by investigator. 3. previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated and without evidence of recurrence for at least 3 years prior to the study. 4. peripheral neuropathy \> grade 2. 5. the patient is pregnant or breastfeeding.
prodromal alpha-synuclein screening in parkinson's disease study

Conditions: Parkinson Disease

Summary: the pass-pd study is set out to screen individuals from the general population with an increased risk for the development of parkinson's disease (pd) and to investigate this highly enriched cohort longitudinally for five year. a special focus is placed on implementation of ethical standards for early risk disclosure in pd.

the pass-pp study is designed to combine the latest developments in clinical and biomarker research to 1. understand the distribution of risk profiles for pd in the general population, especially regarding non-motor symptoms 2. identify subjects with a likelihood of developing pd 3. follow individuals with a high likelihood/risk to develop pd in the future (compared to individuals with low risk and) in a prospective study 4. understand the potential of biological markers to increase prediction of progression/conversion 5. identify subtypes of pd patients, by providing a detailed clinical phenotyping with a main focus on non-motor symptoms cluster 6. provide a framework of ethical handling of early risk disclosure in pd

Eligibility criteria:
inclusion criteria: * age between 50 and 99 exclusion criteria: * presence of clinical pd at the time of study inclusion * other significant neurologic diseases affecting the central nervous system (e.g. multiple sclerosis) * other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment * in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)

Keywords: prodromal alpha-synuclein risk disclosure
abnormalities of b lymphocytes during systemic lupus

Conditions: Systemic Lupus Erythematosus

Summary: previous experimental data strongly suggest that b lymphocytes have intrinsic abnormalities during lupus in mice spontaneously affected by the disease. this study tries to define these abnormalities by looking at the gene expression profile of purified b lymphocytes from patients with non active systemic lupus , compared with the gene expression profile of purified b lymphocytes from healthy donnors.


Eligibility criteria:
inclusion criteria: * non active systemic lupus exclusion criteria: * immunosuppressive drugs * more than 10 mg of prednisone per day

Keywords: systemic lupus b lymphocytes transcriptomas
nanoss bioactive with autograft and bone marrow aspirate in the posterolateral spine

Conditions: Lumbar Spinal Stenosis Secondary to Other Disease

Summary: the purpose of this study is to assess lumbar fusion using nanoss bioactive bone void filler


Eligibility criteria:
inclusion criteria: 1. is at least 21 years of age and skeletally mature. 2. must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between c3 to t1. 3. must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment. 4. has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (anteroposterior/lateral/flexion/extension x-rays \& a recent mri). 5. is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires. 6. is able to understand and sign the patient information sheet/informed consent form. exclusion criteria: 1. requires fusion at more than one level. 2. has had prior fusion at the level to be treated. 3. has a metabolic or systemic bone disorder. 4. has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, paget's disease). 5. has a systemic or local infection (active or latent). 6. has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis). 7. chronic use of steroids, other than episodic use or inhaled corticosteroids. 8. has any significant general illness (i.e., hiv, active metastatic cancer of any type, uncontrolled diabetes type i, dialysis dependent renal failure, symptomatic liver disease). 9. has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation. 10. is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment). 11. has documented allergies to hydroxyapatite or porcine collagen, peek, titanium, titanium alloy or tantalum. 12. is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up. 13. is a smoker. 14. is non-english speaking. 15. requires the use of a bone-growth stimulator. 16. is a prisoner. 17. is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

Keywords: lumbar fusion
respiratory virus infections in acute heart failure

Conditions: Acute Heart Failure Syndrome

Summary: patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus pcr test performed within 72 hours of admission will be enrolled in the study cohort. the detection rate of respiratory viruses including influenza virus, rsv, and coronavirus will be analysed. the investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection.


Eligibility criteria:
inclusion criteria: * adult aged 19 years or older admitted to the cardiology department with acute heart failure * nt-probnp \>300 pg/ml * clinician judgement of possible respiratory viral infection (fever \>38 degrees or cough, respiratory symptoms such as sputum or consolidation on x-ray or crp \>5 mg/dl) * patients who have a nasopharyngeal swab for respiratory virus pcr test performed within 72 hours of admission for any of the 3 reasons exclusion criteria: * patients with a clear other cause of acute heart failure (ex. stemi, bradycardia requiring a pacemaker, sbp \>200mmhg or dbp \>110mmhg, haemoglobin \<7g/dl) * if the cause of pulmonary oedema is prominently attributed to exacerbation of ckd * if there is a clear other source of infection that can explain the fever

Keywords: acute heart failure respiratory virus
clinical evaluation of giomer based varnish versus cpp-acp varnish in the management of dentin hypersensitivity: a randomized clinical trial

Conditions: Dentin Hypersensitivity

Summary: dentin hypersensitivity is a drastic problem, which threaten many dental patients. according to the last published systematic review and meta analysis at 2019, the prevalence of dentin hypersensitivity is being 33.5% among the population. moreover, it was determined that young adults with age range from 18 to 44 years exhibited high percentage (43.9%) of such problem

several approaches to dentin hypersensitivity treatment were proposed to interfere, whether transiently or permanently, with the hydrodynamic theory. these approaches include root coverage and the use of lasers, ions, dentinal sealants, and occluding and nerve depolarization agents, chosen according to the primary cause. there are two major strategies in managing dh; the first is nerve desensitization, and the second is the physical occlusion of the patent tubule. the second approach can be carried out through a wide range of treatment modalities, including the use of proteins, salts or ions to plug the tubules. many agents introduced are capable of sealing dentinal tubules, and can be used to reduce sensitivity. of these agents are cpp-acp varnish and the newly introduced giomer based varnish wilth s-prg technology

Eligibility criteria:
inclusion criteria: * participants of both genders aged 18 to 40 years with good oral hygiene, suffering from pain due to dentin hypersensitivity in at least one tooth exclusion criteria: * taking desensitizing treatment in the last 6 months. (it affects the outcome) * taking anti-inflammatory drugs. (it affects the hypersensitivity perception) * pregnant females. ( they complain from nausea and repeated vomiting attacks) * smokers. (smoking will affect the oral hygiene and periodontal health)
prevention of locally advanced nsclc radiotherapy pneumonia by inhaling beclomethasone propionate

Conditions: Locally Advanced Non Small Cell Lung Cancer

Summary: radical radiotherapy is the main treatment of locally advanced lung cancer, and radiation pneumonia is the main toxic effects of radiotherapy. among them, the fatality rate of severe radiation pneumonia can reach 50%, which is very harmful to tumor patients. at present, the treatment mode of radiation pneumonia is very few, and the therapeutic effect is poor. the prevention of radiation pneumonitis may be the best way to reduce the number of patients with post-radiotherapy pneumonia. previous small clinical studies have shown that the incidence of radiation pneumonia in inhaled beclomethasone group (2 /28) was significantly lower than that in oral prednisone group (8 /29) during radiotherapy. the purpose of this study was to compare the efficacy and safety of radiotherapy between the therapeutic group (inhaled beclomethasone during radiotherapy) and the control radiotherapy group (patients received radiotherapy only), especially the incidence of radiation-induced pneumonia within half a year.

to compare the incidence of radiation pneumonia, effect and side effects of radiotherapy in lung between beclomethasone inhalation therapeutic group and control radiotherapy group in patients with locally advanced non-small cell lung cancer (nsclc) during radiotherapy.

Eligibility criteria:
inclusion criteria: 1. the subjects understood the requirements and risks of the study fully and signed the informed consent form. 2. aged between 18 and 70 years; 3. histologically or cytologically confirmed diagnosis of locally advanced non-small cell lung cancer. 4. all of these patients have pointers to radical radiation and can't be treated surgically. 5. ecog ps of 0-2; 6. women of childbearing age had negative pregnancy tests and were willing to accept drugs or intrauterine contraception, while men of childbearing age were willing to accept contraception voluntarily. 7. adequate hematologic function: peripheral blood neutrophil count \> 2000 cells / ul, platelet count \> 100\*109 / l; hemoglobin \>9.0g/dl; 8. blood total bilirubin \< 2 times normal upper limit, blood ast and alt ≤ 2. 5 times normal upper line; 9. inosine clearance ≥ 60ml / min; 10. life expectancy of at least 12weeks. exclusion criteria: 1. with severe or uncontrolled systemic diseases; 2. with a history of asthma, systemic immune diseases, such as the need for long-term hormone treatment in patients; 3. the lung function decreased obviously; 4. those receiving targeted therapy or biological therapy at the same time; 5. allergic to beclomethasone propionate; 6. pregnant or lactating women; 7. accompanied by uncontrolled diabetes, need to take oral hormone treatment of sarcoidosis and vasculitis, lupus erythematosus and other immune diseases; 8. in recent 5 years has suffered from other tumors: cervical cancer, basal cell carcinoma of the skin, and so on; 9. the estimated survival time was less than 3 months.

Keywords: beclomethasone propionate radiation pneumonitis nsclc radical radiotherapy preventive effect
effect of nutrition and lifestyles on obesity and chronic disease in china

Conditions: Obesity

Summary: this research is aimed at verifying the effects of diets with high protein and low glycemic index (gi) on weight management among overweight or obese chinese adult. additionally, the investigators intend to verify the effects of two new approaches, including food replacement and internet-of-things (iot) monitoring on weight control.


Eligibility criteria:
inclusion criteria: * health adult, age:18-65，bmi（kg/m2）:27.0-40.0 exclusion criteria: * patients under regular medical treatment for chronic diseases like diabetes, hypertension, gout and hyperuricemia. * the patients with chronic renal diseases or other diseases which impose restrictions on the intake of proteins. * mental patients. * people who suffer from secondary obesity caused by endocrine, metabolic disorders or some central nervous system diseases. * people who are under medical or surgical weight-loss treatments in the past three months. * people whose weight fluctuations are not less than 5kg in the past two months； * people with food allergies. * men or women who drink regularly over 25g or 15 g daily,respectively. * pregnant women and women who prepare to be pregnant. * lactating women

Keywords: obesity nutrition intervention food replacement iot
scfe longitudinal international prospective registry

Conditions: Slipped Capital Femoral Epiphyses; SCFE

Summary: slipped capital femoral epiphysis (scfe) is the most common disorder of the adolescent hip and diagnosis and treatment of scfe remain areas of controversy and investigation. the current issues relating to diagnosis stem from an inability to diagnose the condition early on, resulting in increased morbidity. once diagnosed, there are multiple different options for surgical treatment, including in-situ pinning, and the modified dunn procedure. research is ongoing to determine the parameters that should be considered when selecting a procedure to ensure an ideal outcome. in particular, there is a focus on investigating which treatment method may result in lower incidence of avascular necrosis of the femoral head and femoroacetabular impingement (fai), two significant long term concerns associated with scfe. despite myriad published studies on scfe, very few are prospective and most lack sufficient patient numbers for clinically meaningful comparative analysis. the aim of this study is to develop a multi-center, international prospective registry of patients with scfe to facilitate the comprehensive examination of clinical, functional and radiographic outcomes of each treatment, in relation to specific parameters determined prior to intervention. the general registry will serve as a hypothesis-generating database of prospectively collected outcomes. in turn, this will facilitate the development of targeted, hypothesis-testing randomized controlled trials and observational studies that can be housed within the larger registry.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of scfe * intend to receiving follow-up at participating centre * less than 18 years old at time of admission * adequate diagnostic information and radiographic imaging (for patients previously treated for scfe) exclusion criteria: * no definitive diagnosis of scfe * do not intend to receive follow-up at a participating centre * greater than 18 years old at time of admission * prior treatment for scfe not appropriately documented * known or suspected underlying conditions (e.g., cerebral palsy, spina bifida, or osteogenesis imperfecta)
sufentanil in patients with lower extremity fracture surgery myocardial damage function study

Conditions: Myocardial Injury

Summary: 1. to analyze the association of different doses of opioids on myocardial injury/protection through bmp-6/smad pathway. 2. to observe the effect of different doses of opioids on the expression of bmp-6 in bone marrow. 3. to investigate the relationship between different doses of opioids and bmp-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.

this study explored the important role of bmp6/smad pathway in myocardial/injury protection by observing the effects of different doses of opioids on myocardial injury indexes hs-ctni and bmp-6 related indexes in patients undergoing lower extremity fracture surgery, as well as the changes of bmp6 expression in bone marrow tissue of fracture end. the relationship between different doses of opioids and bmp6 and cardiac adverse events provides a theoretical basis for clinical rational drug use.

Eligibility criteria:
inclusion criteria: * there were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture. * asa grades i to iii, gender is not limited. exclusion criteria: * patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury. * old fracture * stroke patients * liver cirrhosis, kidney failure * serious systemic infections, alcoholism, drug dependence * pathological fracture * use of glucocorticoids in the past one month * diabetic
andexanet alfa: non-interventional study in stroke units in germany (de)

Conditions: Intracranial Hemorrhages

Summary: the multicenter, prospective, observational, non-interventional study conducted in german stroke units is investigating patients with intracranial hemorrhage (ich) under effective anticoagulation with rivaroxaban or apixaban. the aim of the study is to analyze under routine conditions wether the volume increase of ich under treatment with rivaroxaban and apixaban can be reduced with the antidote andexanet alfa. thus, data of patients under effective treatment with rivaroxaban or apixaban and treated with andexanet alfa at baseline will be assessed at the time of onset of ich, during the hospital stay and during a follow-up by telephone at 30 and 90 days after hospital discharge. the main objective is defined as the change in size or volume of the hematoma by computed tomography (ct) or magnetic resonance imaging (mri) in patients with ich under effective treatment with rivaroxaban and apixaban, who are treated with andexanet alfa. further objectives comprise evaluations concerning the functional status according to modified rankin scale (mrs), changes in the national institutes of health stroke scale (nihss), and occurrences of ich or new intraventricular bleeding as well as mortality rates.


Eligibility criteria:
inclusion criteria: * age ≥18 years at enrollment * patients willing and able to provide written informed consent for data transmission. for patients who are not legally competent to sign this informed consent for data transmission exceptions/special cases are defined (details provided in the study protocol) * patients with primary intracranial hemorrhage as confirmed with ct or mri. * patients under effective anticoagulation treatment with rivaroxaban or apixaban at the time of admission, according to the judgement of treating physician and determined using point-of-care (poc) anti-factor xa (fxa) assays or laboratory-based anti-fxa measurement. * patients treated with andexanet alfa * signed informed consent as soon as possible after start of symptoms of initial ich event, but before discharge exclusion criteria: * start of symptoms of initial ich event \> 24 h before admission to hospital

Keywords: intracranial bleeding andexanet-alfa rivaroxaban apixaban anticoagulation
the effect of e-mobile and written education

Conditions: Quality of Life; Sleep; Education; Counseling; Nursing

Summary: bening's prostate hyperplasia (bph), which is closely related to aging, is one of the most common diseases in the world. although it is not a life-threatening condition, lower urinary tract symptoms (luts) are seen in many patients, which disrupts their daily activities, sleep patterns, and quality of life of the patients. examination of changes in sleep and quality of life after transurethral resection of the prostate (tur-p) in patients with luts due to bph and planning training according to their needs will positively affect the lives of these patients. it is very important for nurses to provide individual training and counseling by making use of innovative technology to ensure that patients manage the surgical process in a healthy way and cope with possible complications. this thesis study was planned as a three-group randomized controlled experimental study in order to determine the effect of e-mobile training and counseling on quality of life and sleep in patients who underwent tur-p to manage the operative process and cope with possible complications.

this thesis study aims to determine the effect of e-mobile training and counseling on quality of life and sleep in patients who underwent tur-p for bph, to manage the operation process and to cope with possible complications, and to determine the effectiveness of the written training given to the patients, the control group and the e-mobile application designed for comparasion.

Eligibility criteria:
inclusion criteria: - being literate, not having communication, hearing and visual impairments, not having any psychiatric disorders, not having sleep apnea, using a smartphone for at least 1 year in the experimental group, exclusion criteria: -the patient's refusal to participate in the study